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Protein kinase C signals thromboxane induced increases in fibronectin
synthesis and TGF.p bioactivity in mesangial cells. Previous studies have
demonstrated that thromboxane (TX) stimulates matrix protein synthesis
in mesangial cells (MC), and that this action is signalled by receptor
mediated activation of protein kinase C (PKC). In the present study, we
examined the hypothesis that activation of PKC by TX signals increases in
transforming growth factor /3 (TGF-/3) bioactivity, which in turn induces
enhanced matrix protein synthesis. In cultured rat MC, the TXAJ
prostaglandin endoperoxide analogue U-46619, but not exogenous human
platelet TGF-/31, activated PKC as reflected by enhanced in situ phosphor-
ylation of MARCKS protein, an endogenous substrate of PKC. U-46619
and TGF-/31 stimulated fibronectin (Fn) synthesis in MC, as shown by
[35S]methionine incorporation into immunoprecipitable Fn. Pan-specific
rabbit anti-TGF-f3 antibody blocked the increases in Fn synthesis induced
by exogenous TGF-/3 and those induced by U-46619 at 24 to 72 hours after
addition. Anti-TGF-/3 antibody did not block the small increases in Fn
synthesis observed six hours after addition of U-46619, suggesting that this
acute response was not dependent on TGF-/3. Anti-TGF-13 antibody also
failed to block activation of PKC by U-46619. U-46619 and 50 n of the
PKC agonist phorbol dibutyrate (PDBu) significantly increased both the
active fraction and total (latent plus active) TGF-/3 in MC culture media,
as assayed with the mink lung epithelial cell bioassay system. PKC
inhibition with bisindolylmaleimide GF 109203X (GFX) or down-regula-
tion of PKC in MC by prior exposure to a high concentration (0.5 j.tM) of
phorbol myristate acetate (PMA) blocked increases in TGF-/3 bioactivity
induced by either U-46619 or PDBu. PKC down-regulation in MC also
blocked increases in Fn synthesis induced by U-46619. By contrast,
exogenous TGF-/3 stimulated Fn synthesis in both intact MC and in MC
with down-regulated PKC. The findings indicate that activation of PKC by
U-46619 signals an increase in TGF-j3 bioactivity, which in turn stimulates
Fn synthesis in MC by processes not dependent on PKC.
Thromboxane (TX) has been implicated in the pathogenesis of
renal injury in experimental models of nephropathy, as well as in
some human renal disorders [1—71. Thus, TX synthetase inhibitors
ameloriate pathological changes in the kidneys of patients with
cyclosporine toxicity [3], and prevent increases in basement
membrane protein mRNA levels in the kidneys of diabetic mice
[7]. TX antagonists improve renal function in lupus nephritis [4],
and in post-obstructive nephropathy [5], as well as preventing
albuminuria and increases in glomerular matrix expansion in the
streptozotocin diabetic rat [6]. Many earlier studies focused on
the actions of TX as a platelet aggregator and vasoconstrictor in
the mediation of renal dysfunction [8]. However, direct effects of
TX on the mesangial cell (MC) have now been demonstrated that
may contribute to the development of glomerulosclerosis. Brugge-
man et al found that TX increases human MC synthesis of type IV
collagen, laminin, and fibronectin and the mRNA levels of these
proteins [9, 10]. Mene et al similarly showed that TX stimulates
protein synthesis, including collagen type IV, in cultured human
MC [11]. Fibronectin (Fn) accumulation is also increased in rat
MC exposed to TX and a high ambient concentration of glucose
[12]. The pathways through which TX induces changes in MC
matrix protein synthesis are incompletely understood. MC have
high affinity TX receptors [13, 14]. Upon binding to these
receptors, TX activates phospholipase C, stimulates increases in
inositol phosphate turnover, elevates cytosolic calcium and diacyl-
glycerol, and activates protein kinase C [14—17]. Recent studies in
our laboratory [17] have implicated rapid activation of protein
kinase C (PKC) by TX as a signal for increased Fn synthesis in
MC. However, the pathway by which activation of PKC subse-
quently initiates an increase in Fn synthesis in MC is not known.
Transforming growth factor J3 (TGF-/3) is a potent stimulus of
MC matrix protein synthesis and also inhibits degradation of these
proteins [18, 19]. There is now strong evidence to support a
pathogenetic role for TGF-j3 in glomerulosclerosis [20—26], in-
cluding the demonstration in vivo that renal transfection with
cDNA for TGF-/31 leads to the development of this histologic
change [27]. In preliminary studies, we found evidence of a role
for TGF-f3 in the expression of the action of TX to increase Fn
synthesis in MC after 24 hours [28]. Thus, anti-TGF-f3 antibody
blocked TX induced increases in Fn synthesis in MC, and TX
increased TGF-13 bioactivity in MC culture media [28]. TGF-f3 has
similarly been implicated in the mediation of several other agents
to increase MC matrix protein synthesis, including high ambient
concentrations of glucose [29], low density lipoproteins [30] and
angiotensin II [31]. Notably, all of these stimuli of matrix protein
synthesis activate PKC [30, 32, 33]. In the present study, we
examined the possibility that TX activation of PKC is a signal to
increase TGF-/3 bioactivity in MC, which in turn mediates the
sustained increases in Fn synthesis observed in response to TX.
Methods
Rat MC culture
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MC were cultured from collagenase treated glomerular cores
obtained from the kidneys of 120 to 150 g female Sprague-Dawley
rats by graded sieving as previously reported [12]. They were
maintained in RPMI-1640 medium supplemented with 15% fetal
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calf serum (FCS), 100 U/mi penicillin, 100 g/ml streptomycin, 5
g/ml insulin, 5 jg/m1 transferrin, and 5 nglml sodium selenite
(Sigma Chemical Co., St. Louis, MO, USA) at 37°C in 5% CO2
and 95% air. At confluence, MC were routinely rendered quies-
cent by incubation in media with FCS reduced to 1% for 24 hours.
Test agents were then added. Cell passages 2 to 8 were used in
these studies.
Bioassay of TGF-J3 activity
TGF-13 bioactivity in MC culture media was assayed using the
mink lung epithelial cell (MLEC) assay with minor modifications
of published procedures [34, 35], as previously reported from this
laboratory [30]. Briefly, media were collected from MC cultured
as described in the figure legends. Bovine serum albumin (BSA)
and protease inhibitors were added to final concentrations of 1
mg/ml BSA and 1 g/ml each of aprotinin, leupeptin, and
pepstatin. The samples were centrifuged to remove cell debris and
held at 4°C until assayed. Latent TGF-13 was activated by heating
media to 80°C for 15 minutes. MLEC, American Type Culture
CCL-64, were seeded in MEM supplemented with 10% FCS,
antibiotics, and glutamine. After six hours, medium FCS was
reduced to 0.5% and the culture continued for 18 hours. Media
from MC cultures or an equivalent volume of unconditioned MC
media (RPMI-1640) containing exogenous TGF-131 standards
were added to the MLEC. After 24 hours, the cells were pulse
labeled with [3H]-thymidine (New England Nuclear, Boston, MA,
USA) for two hours, washed with phosphate buffered saline
(PBS), and the incorporation of [3H]-thymidine into TCA precip-
itable material determined by liquid scintillation counting. Stan-
dard curves for TGF-j31 bioactivity were prepared using exoge-
nous human TGF-131 (0.1 to 10 pM). Inhibition of MLEC [3H]-
thymidine ranged from 92% (10 M exogenous TGF-13) to 3% (0.1
M TGF-13), with an IC50 of approximately 0.7 M under the assay
conditions used. Media samples were diluted to fall within the
range of the standard curve. Unconditioned MC media containing
the final concentrations of agonists and inhibitors present in
media from MC cultures were employed as controls in the
bioassay system. The extent to which the action of culture media
from MC to inhibit [3H]-thymidine incorporation in MLEC was
attributable to TGF-13 bioactivity was examined by addition of 30
g/ml of anti-TGF-13 antibody to the media samples prior to
bioassay. Anti-pan specific TGF-f3 antibody, but not control rabbit
IgG, completely abrogated the effects of MC culture media to
suppress [3H]-thymidine incorporation in MLEC, as previously
reported [30].
Fn synthesis
Fn synthesis was measured as [35S]-methionine ([35S]-Met)
incorporated into immunoprecipitable material extracted from
the cells plus matrix after a four-hour pulse label as described in
the figure legends. MC were grown to confluence, FCS reduced to
1%, and agonists added as described. After culture for the times
indicated, the cells were washed twice with PBS and incubated in
methionine-cysteine-deficient minimum essential media (MEM)
with 25 j.tCi of [35S]-Met (Tran35S-label, ICN, Irvine, CA, USA).
[35S]-Met labeled Fn was immunoprecipitated with human Fn
antiserum (Collaborative Research Inc., Bedford, MA, USA) and
assayed as previously described [12]. Fn synthesis is expressed as
dpm/103 cells or dpm/.tg protein, determined using bicinchoninic
acid (Sigma Chemical Co.).
PKC activity
In situ PKC activity was determined as previously reported in
detail from this laboratory [12, 17]. Briefly, MC were grown to
confluence, media serum reduced to 1%, and the cells labeled
with 32P-orthophosphate (New England Nuclear, Boston, MA,
USA) for four hours. MC were exposed to test agents as described
in the figure legends and the acid soluble 80 kD myristoylated
alanine rich C kinase substrate (MARCKS) protein extracted and
separated by electrophoresis. The PKC data are expressed as
density units, calculated as the ratio of the phosphorylation of the
80 kD MARCKS protein to a 40 kD reference protein, whose
phosphorylation did not change under the conditions studied.
Materials
Materials were obtained from sources noted above, or as
previously reported [30].
Statistics
Experiments were performed at least three times and data
shown as means SE. Each incubation condition was represented
by duplicate or triplicate wells. Replicates from a single culture
were averaged and entered as one value for purposes of statistical
analysis. ANOVA was performed to compare multiple groups,
and the significance of differences between mean values was
determined by Student's t-test.
Results
Fn synthesis in MC exposed to 1 jM of the TXA2/prostaglandin
endoperoxide analog U-46619 for 24 hours was approximately
2.5-fold higher than control (Fig. 1). As previously reported [17],
this concentration of U-46619 induced maximal increases in Fn
synthesis at 24 hours. As is also shown in Figure 1, 1 M exogenous
TGF-f3 also stimulated Fn synthesis in MC. The latter was the
lowest concentration of exogenous TGF-13 to increase Fn synthe-
sis after 24 hours significantly, although small and variable
increases were observed in response to 0.5 M TGF-p. Maximal
(up to 5-fold) increases in Fn synthesis were observed in response
to 50 pM TGF-f3 (not shown). Neither U-46619 nor TGF-13
significantly altered MC number after 24 hours, and the increases
in Fn synthesis were evident whether expressed on the basis of cell
number (Fig. 1) or culture protein content (not shown). As is also
shown in Figure 1, the addition of 30 g/ml pan-specific anti-
TGF-/3 antibody to the cultures five minutes before U-46619 or
TGF-13 blocked the increase in Fn synthesis induced by both
agents. By contrast, the Fn synthetic response to U-46619 or
TGF-13 in the presence of 30 Wml control rabbit IgG (Fig. 1) did
not differ from responses in the absence of IgG (not shown).
Phosphorylation of the 80 kD MARCKS protein was increased
twofold 15 minutes after exposure of MC to U-46619, and
anti-TGF-/3 antibody had no effect on this response (Fig. 1). In
contrast to U-46619, however, concentrations of exogenous
TGF-3 from 1 p (Fig. 1) to 50 M (not shown) failed to alter
MARCKS protein phosphorylation.
Figure 2 shows the effects of U-46619 and exogenous TGFj3 on
FN synthesis in MC with intact PKC and in cells whose PKC had
been markedly downregulated by exposure to 0.5 LM phorbol
myristate acetate (PMA) for 24 hours prior to the addition of
U-46619 or exogenous TGF-p1. Sustained exposure of MC and
other cells to this concentration of PMA decreases PKC activity to
424 Studeret a!: Activation of PKC by U-46619
U)
>...
Ci)
-..CEpCCoIL
LLc
.5
o .
A
*
f
B
Vehicle PMA
125
100
75
50
25
0
0.6
0.5
0.4
0.3
0.2
0.1
0
IgG Anti-TGFI3
Fig. 1. Effects of U-46619 and TGF-13 on mesangial cell PKC activity (B)
and fibronectin iynthesis (A) in the presence and absence of antibody to
TFG-/3. Mesangial cells were grown to confluence in 15% FCS and
medium changed to contain 1% FCS for 24 hours to growth arrest cells
prior to addition of test agents. Eighty kD MARCKS phosphorylation was
determined 15 minutes after the addition of 1 pivi TGF-/3, or 1 ILM U-46619
in the presence of 30 sWml of control rabbit IgG or pan-specific TGF-13
antibody. Fibronectin synthesis was determined 24 hours after addition of
TGF-/3 or U-46619. Control IgG alone did not affect PKC activity or Fn
synthesis in MC. Symbols are: (LI) control; () U-46619; (U) TGF-13.
Values are means se (N = 4). *P < 0.05 versus corresponding control.
less than 2% of control values [12, 17, 36]. As shown in Figure 2,
PKC down-regulation had no significant effect on basal Fn
synthesis. Moreover, in contrast to U-46619 which stimulated Fn
synthesis only in MC with intact PKC, exogenous TGF-p stimu-
lated Fn synthesis in MC with either intact or down-regulated
PKC.
Figure 3 shows the effects of 1 sM U-46619 on TGF-/3 bioac-
tivity in media of MC cultures. U-46619 increased the active form
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Fig. 2. Effect of PKC down-regulation on TGF-13 and U-46619 stimulated
fibronectin synthesis in mesangial cells. Mesangial cells were grown to
confluence as described in Figure 1. Where indicated, PKC was down-
regulated by exposure to 0.5 sM PMA for 24 hours; the DMSO vehicle(0.05%) for PMA was added where indicated. After 24 hours, media was
changed, and the culture continued for 24 hours with PMA or vehicle and
other test agents as indicated. Fibronectin synthesis was determined 24
hours after addition of TGF-13 or U-46619. Values are mean se (N = 4).
Symbols are: (LI) control; () TGF3; (•), U-46619. < 0.05 versus
corresponding control. < 0.05 versus corresponding U-46619 value in
vehicle treated cells.
of TGF-J3 in media by 145% over basal (0.53 M to 1.3 pM), and
increased total (latent + active) TGF-/3 bioactivity by 43% (32 to
46 pM). Figure 3 also shows the effects on these TGF-13 bioactiv-
ities of bisindolylmaleimide GF 109203X (GFX), a potent and
relatively specific inhibitor of PKC [361. We have previously
shown that GFX blocks the Fn synthetic response to U-46619 in
MC [17]. GFX did not alter basal accumulation of total TGF-f3
bioactivity in media, but suppressed the basal level of the active
fraction to 30% of the value observed in cultures exposed to the
GFX vehicle alone. By contrast, GFX completely blocked the
increases in both active and total TGF-f3 bioactivity induced by
U-46619.
The role of PKC in the expression of the action of U-46619 to
increase TGF-13 bioactivity in MC cultures was further examined
in MC whose PKC was down-regulated by exposure to PMA for
24 hours prior to the addition of U-46619 (Fig. 4). U-46619 failed
to increase TGF-13 bioactivity in media of MC whose PKC had
been down-regulated. Consistent with the effects of GFX shown in
Figure 3, PKC down-regulation had no effect on basal accumula-
tion of total TGF-13. However, the basal level of the active fraction
of TGF-13 in media was significantly reduced compared to that
seen in media of control MC cultures.
Figure 5 shows the effect of a low concentration (50 nM) of the
PKC agonist phorbol dibutyrate (PDBu) on TGF-13 bioactivity in
media from MC. Low concentrations (50 to 100 nM) of PDBu
have been shown to rapidly (15 mm) activate PKC in MC [12].
Despite a decline in the total PKC content of MC to 50 to 60% of
initial values, PKC activation in MC in response to 50 to 100 flM
PDBu is sustained for at least six days, as reflected by a persistent
enhancement of MARCKS protein phosphorlyation [12]. As
shown in Figure 5, 50 nM PDBu significantly increased the
Studer et a!: Activation of PKC by U-46619 425
Vehicle GFX
Fig. 3. Effects of U-46619 on TGF-p bioactivity in mesangial cell culture
media in the presence and absence of the PKC inhibitor GF 109203X (GFX).
(A) Active; (B) latent + active. Mesangial cells were grown to confluence
as described in Figure 1. GFX (2 gal), or the vehicle for GFX (0.05%
DMSO) was added where indicated, followed 15 minutes later by the
addition of 1 gM U-46619. After 24 hours of culture, medium was
harvested for determination of TUF-3 bioactivity. Total TGF-j3 bioactivity
(latent plus active) was determined in media samples after heat activation.
Values are mean SE (N = 3 to 5). Symbols are: (0) control; (0)
U-46619. tP c 0.05 versus corresponding control. < 0.05 versus
corresponding value in the vehicle treated cells.
Vehicle PMA
Fig. 4. Effects of PKC downregulation on basal and U-46619 mediated
changes in TGF-f3 bioactivity in mesangial cell culture media. (A) Active; (B)
active + latent. Mesangial cells were grown to confluence as described in
Figure 1, and PMA (0.5 sM) or DMSO vehicle (0.05%) was added for 24
hours as indicated. Medium was then changed and 1 1kM U-46619 added
to some wells. Culture was continued for an additional 24 hours in the
presence of PMA or its vehicle with or without U-46619, as indicated. The
conditioned media were harvested and assayed for TGF-!3 bioactivity.
Values are mean SE (N = 4). p < 0.05 versus corresponding control.
**p < 0.05 versus corresponding value in the vehicle treated cells.
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concentration of active and total TGF-13 in media of MC cultured
in the presence of this agent for 24 hours. By contrast, in MC
whose PKC had been down-regulated by prior exposure to PMA,
subsequent addition of 50 nM PDBu failed to increase either
active or total TGF-p bioactivity (Fig. 5). As noted above, PMA
also reduced the basal levels of active but not total TGF-p.
The preceding studies showed that inhibition of PKC decreased
and activation of PKC increased the fraction of total TGF-f3 in the
active state. In media of control MC cultures, 3.1% of the total
TGF-j3 was in the active form. In MC exposed to GFX for 24
hours, this value was reduced to 1.1%. After 48 hours exposure of
MC to 0.5 tM PMA, the active fraction of TGF-f3 in media was
1.5% of total activity. In MC cultured with U-46619, the fraction
of total TGF-/3 in the active form was 5.6%. PDBu also increased
the percentage of TGF-fJ in the active form to approximately 4%
(Fig. 5).
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Fig. 5. Effects of PKC down-regulation on PDBu mediated changes in
TGF-(3 bioactivity in mesangial cell culture media. Mesangial cells were
treated as described in Figure 3 and culture media harvested 24 hours
after addition of 50 nM PDBu to vehicle or PMA treated cells. Symbols
are: (0) control; () PDBu. Values are means SE (N = 4). *P < 0.05
versus corresponding control. **P < 0.05 versus corresponding value in
the vehicle treated cells.
Figure 6 shows the time course of U-46619 action on accumu-
lation of TGF-p bioactivity in MC culture media. The earliest
time point after addition at which U-46619 induced a significant
increase in either active or total TGF-p was six hours. Compared
to corresponding control values, U-46619 also increased accumu-
lation of active and total TGF-J3 at 24, 48, and 72 hours.
Concurrent increases in Fn synthesis occurred over this period, as
previously reported [17]. However, while anti-TGF-j3 antibody (30
pg/mI) blocked increases in Fn synthesis induced by U-46619 from
24 to 72 hours, it did not alter the 40% increase in Fn synthesis
observed at six hours (IgG, 62 5 dpm/103 cells; anti-TGF-/3, 64
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Fig. 6. Time course of the effect of U-46619 on TGF-p bioactivity in
mesangial cell culture media. Mesangial cells were treated as described in
Figure 1 and media harvested at the times indicated for determination of
TGF-/3 bioactivity. Values are mean SE (N = 3 to 6) (data for active and
latent TGF-j3 at six hours have been multiplied by a factor of 2). Symbols
are: (0) control; () U-46619. < 0.05 versus corresponding control.
5; U-46619 + IgG, 85 7; U-46619 + anti-TGF-j31, 82 8).
The dose of anti-TGF-131 antibody employed in these studies was
sufficient to block the 50% increase in Fn synthesis induced in MC
exposed to 25 M exogenous TGF-13 for six hours. By contrast, 2
LM GFX blocked U-46619 induced increases in both TGF-j3
bioactivity and Fn synthesis at six hours and at the later time
points.
Discussion
Previous studies have indicated that the action of TX to
stimulate Fn synthesis by MC is signalled by activation of PKC
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[17] and is dependent on TGF-f3 bioactivity [28]. The current
findings are consistent with the hypothesis that activation of PKC
by TX in MC signals an increase in TGF-p bioactivity, which in
turn mediates the increases in Fn synthesis that occur in MC
exposed to TX for 24 hours or longer. Thus, anti-TGF-J3 antibody
suppressed increases in Fn synthesis induced by either exogenous
TGF-13 or culture of MC with U-46619 for 24 hours or longer. By
contrast, anti-TGF- antibody did not alter the U-46619 activa-
tion of PKC. Accordingly, TGF-j3 antibody did not impair the
initial steps of the TX signalling pathway, specifically the TX-
receptor interaction and activation of PKC which have previously
been linked to expression of TX effects on Fn synthesis in MC
[17]. Moreover, U-46619 and the PKC agonist PDBu significantly
increased both active and total TGF-13 bioactivity in media of
cultured MC. GFX, a potent inhibitor of PKC [37], blocked
U-46619 induced increases in these bioactivities. These findings
all support a role for PKC in transduction of U-46619 effects on
TGF-/3 bioactivity. Although the IC50 of GFX for PKA and
phosphorylase kinase are 200 and 70 times greater, respectively,
than that for PKC [371, the inhibitory action of GFX is not entirely
selective for PKC relative to other kinases. Accordingly, the
influence of down-regulation of PKC in MC was also examined to
assess further the role of PKC in expression of U-46619 stimu-
lated increases in TGF-13 bioactivity. As shown in Figure 2 and
previously reported [17], down-regulation of PKC by prior expo-
sure of MC to PMA blocked the action of U-46619 to increase Fn
synthesis. The present data demonstrate that PKC down-regula-
tion also prevented the increases in TGF-13 bioactivity in MC
culture media induced by both U-46619 and PDBu. In contrast,
down-regulation of PKC failed to alter the increases in Fn
synthesis induced in MC by exogenous TGF-p. These latter
findings, and the failure of exogenous TGF-p to activate PKC in
MC (Fig. 1), suggest that the action of TGF-/3 on Fn synthesis in
these cells is not dependent on PKC. However, since not all PKC
isozymes are down-regulated by phorbol ester [38], it is possible
that PKC isoforms such as PKC-&, which is resistant to down-
regulation, could be involved in the expression of actions of
TGF-13 on Fn synthesis.
The concentrations of both active and latent TGF-j3 found in
MC culture media in the current studies are low relative to those
previously reported by Kaname et a! [35] and Kagami et al [31].
With respect to the active fraction, these groups reported basal
media concentrations of TGF-j3 of 14 M after 24 hours [35] and
10 M after 48 hours culture of MC [31]. The fraction of active
TGF-p constituted 4% [35] and 12% [31] of total TGF-f3 bioac-
tivity under basal MC incubation conditions, compared to 3.1% in
the present study. Whether these differences are a function of the
MC culture conditions, the processing of the media prior to
bioassay (addition of protease inhibitors, dialysis of samples) or
other factors is not certain. The concentrations of TGF-p detected
in MC culture media in the present study are also much lower
than the concentrations of exogenous TGF-13 often used [39—42]
to stimulate increases in mRNA levels for Fn (40 to 800 pM) or
protein and collagen synthesis (10 to 120 pM) in MC. In the
current study, increases in Fn synthesis by MC were observed in
response to concentrations of TGF-p1 as low as 1 M (Fig. 1), with
maximal stimulation in response to 50 p. The responsiveness of
Fn synthesis to TGF-13 in MC thus approximates that of collage-
nase sensitive proline incorporation which was maximally stimu-
lated by 10 M TGF-p [42]. MacKay et al also found that high
affinity binding of TGF-/3 in MC was saturated at a concentration
of between 10 and 15 p, with a kD of 5 M [42]. The concentra-
tion response relationship observed between TGF-f3 and fibronec-
tin synthesis is therefore consistent with the reported kD for
TGF-p in MC. Although the basal levels of active TGF-J3
observed in the present study are below those previously reported
in culture media of MC, the increases in active TGF-)3 (0.53 to 1.3
p, Fig. 3) induced by 24 hours of exposure to U-46619 appear
sufficient to mediate the action of U-46619 on Fn synthesis, at this
time, in view of the sensitivity of this parameter to a concentration
of exogenous TGF-!3 as low as 1 p. The low basal levels of active
TGF-j3 in the control MC which had been rendered quiescent by
prior reduction in the concentration of FCS in the culture media
probably did not modulate Fn synthesis in the control cells. This
is implied by: (a) the failure of PKC inhibition or down-regulation
to alter basal rates of Fn synthesis despite a concurrent reduction
in active TGF-; and (b) the absolute concentration of active
TGF-f3 in media under control conditions (0.6 M or less), which
was below the minimal concentration of exogenous TGF-p (1 pM)
effective in stimulating Fn synthesis.
In contrast to the inhibitory action of anti-TGF-13 antibody on
increases in Fn synthesis observed in MC exposed to TX for 24
hours or longer, anti-TGF-j3 antibody failed to block the 40%
increases in Fn synthesis after only six hours of culture with TX.
Moreover, the small increases in the active fraction of TGF-f3
(<0.5 pM) observed after this brief exposure to U-46619 were
likely inadequate to account for the corresponding early increases
in Fn synthesis, since 25 M exogenous TGF-p yielded only
modest increases in Fn synthesis in this time frame. In our earlier
studies [17], we demonstrated that inhibition or down-regulation
of PKC activity prevented both the early (6 hr) and later increase
in Fn synthesis induced by TX. In the current study, PKC
inhibition with GFX similarly blocked both the early and subse-
quent increases in TGF-(3 induced by TX. Nevertheless, the
failure of antibody to TGF-p to block the acute effects of TX on
Fn synthesis suggest that this action is not dependent on TGF-13.
In this regard, serum, a potent activator of PKC [12], rapidly
increases Fn gene expression [43]. Similarly, Naham, Rovin and
Leonhart [44] reported increases in Fn mRNA in MC 30 minutes
after exposure to phorbol ester, with subsequent increases in both
matrix and medium Fn content by four hours. These rapid
responses and the acute increases in Fn synthesis induced by TX
may reflect genomic effects of PKC expressed independent of
TGF-j3.
A number of prior observations have implicated PKC as a signal
for increased TGF-13 synthesis and/or secretion. Thus, Akhurst,
Fee and Balmain reported phorbol ester induced TGF-$3 mRNA
in epidermal cells [45]. Moreover, regions in the TGF-13 gene that
are responsive to phorbol ester have been identified [46]. PKC has
also been implicated in increases in TGF-p mRNA [33, 35] and
TGF-13 bioactivity [47] observed in vascular smooth muscle cells.
In MC, several activatOrs of PKC in addition to phorbol ester and
U-46619 have now been shown to increase TGF-3 mRNA levels,
bioactivity, or both. These include high concentrations of glucose
[29], angiotensin II [31], and low density lipoproteins [30], all of
which also increase MC matrix protein synthesis. Ziyadeh et a!
[29] found that high concentrations of glucose, which activate
PKC via de novo synthesis of diacyiglycerol [48], stimulate in-
creased TGF-13 mRNA by murine MC. Kagami et al [31] showed
that angiotensin II, another known agonist of PKC [49], increased
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TGF-/3 mRNA levels in rat MC and TGF-f3 bioactivity in MC
culture media. We recently found that exposure of rat MC to low
density lipoproteins activated PKC and increased media TGF-/3
bioactivity [30]. Analogous to the finding with U-46619 in the
present study, inhibition or down-regulation of PKC activity in
MC prevented the increases in TGF-13 bioactivity induced by low
density lipoproteins [30].
By contrast, our findings do not implicate PKC isoforms that
are down-regulated by phorbol esters or inhibited by GFX in the
pathway by which TGF-/3 stimulates Fn synthesis in MC. Thus,
exogenous TGF-13 failed to activate PKC (Fig. 1), and down-
regulation of PKC in MC (Fig. 2) or the PKC inhibitor GFX (data
not shown) failed to alter the increases in Fn synthesis induced by
exogenous TGF-/3. There are data both supporting and rejecting
a role for PKC activation in the mediation of TGF-13 effects on cell
function. Muldoon, Rodland and Magun [50] reported that
prolonged treatment of fibroblasts with TGF-p stimulated cal-
cium influx and phosphatidylinositol turnover, while Markovac
and Goldstein [51] found that TGF-f3 caused a redistribution of
PKC from the cytosolic to particulate fraction in microvessels of
rat brains. More recently, Bradham et a! [52] concluded that
activation of PKC was necessary for TGF-p induced down-
regulation of collagen II expression in chondrocytes. However,
this was based on studies utilizing the serine/threonine protein
kinase inhibitor H-7. Ohtsuki and Massague [531 had previously
shown that H-7 inhibits responses to TGF-13 by interfering with a
phosphorylation step unrelated to PKC. Results of two recent
studies are consistent with our findings in MC. Anderson et a! [54]
reported that TGF-/3 did not activate PKC in either LLC-PK1 or
MDCK renal epithelia! cell lines, and Mu, Ware and Kent [55]
found analogous results in vascular smooth muscle cells derived
from human saphenous veins. Thus, TGF-j3 may activate PKC in
some cells, but this action is not apparent in MC and other renal
cell lines.
As noted above, increases in TGF-f3 mRNA, TGF-j3 bioactivity,
or both have been found in response to activators of PKC,
including phorbol ester, glucose, low density lipoproteins, and
angiotensin II [29—31, 33, 35, 42, 43]. In the present study,
U-46619 and phorbol ester increased latent TGF-f3 and this action
was also linked to activation of PKC. In view of earlier reported
changes in mRNA levels for TGF-13, the increases in latent TGF-/3
bioactivity observed in response to U-46619 and phorbol ester in
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Fig. 7. Proposed pathway by which activators of
PKC may contribute to mesangial matrix
&pansion via increases in TGF-f3. See text for
explanation.
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MC may reflect PKC induced increases in TGF-13 synthesis, and
perhaps a direct genomic action of PKC [45]. However, the
conversion of TGF-/3 from the latent to the active form is thought
to be a critical determinant of expression of the biologic action of
TGF-13, and one that may be physiologically regulated [56]. In the
present studies, only a small proportion of total TGF-f3 (3%) in
MC culture media was present in the active form under control
conditions. This proportion fell to even lower levels (1%) when
PKC was inhibited or down-regulated, whereas basal levels of
latent TGF-f3 did not change. Conversely, the active fraction rose
modestly (4 to 5%) in response to U-46619 and phorbol ester, an
increase that was prevented by PKC inhibition or down-regula-
tion. There have been no studies of TGF-f3 activation by MC in
culture. However, marked increases in the active relative to the
latent fraction of TGF-p were observed in MC exposed to
angiotensin II, consistent with an independent action of this agent
on TGF-13 activation [31]. In smooth muscle and endothelial cell
co-cultures, activation of TGF-p requires a close apposition of the
two cell types and involves the conversion of plasminogen to the
proteolytic active plasmin by plasminogen activation [56—58].
Plasmin then cleaves at the amino terminus of the propeptide and
releases active TGFI3. PKC has been shown to induce tissue-type
plasminogen activator (tPA) in some cells [59]. Moreover, human
MC synthesize and secrete tPA [60]. Accordingly, it is possible
that U-46619 stimulation of PKC may increase tPA, and thereby
enhance activation of latent TGF-f3 via an increase in plasmin. In
preliminary studies (unpublished observations), we have observed
that aprotinin, a protease inhibitor which suppresses plasmin
activity, abolished increases in the active fraction of TGF-13
induced in MC by PDBu. This is consistent with PKC mediated
induction of proteolytic activity in the process of TGF-/3 activation
in MC.
In conclusion, the current findings show that activation of PKC
in MC by TX increases TGF-p bioactivity. The latter in turn
stimulates sustained increases in Fn synthesis in MC by processes
not dependent on PKC. They provide further evidence for the
schema shown in Figure 7, which summarizes our current under-
standing of potential mechanisms that may be common to several
stimuli which enhance MC matrix protein accumulation in vitro,
and may also contribute to the development of glomerulosclero-
sis. TX, angiotensin II, and low density lipoproteins bind to
specific membrane receptors, stimulate phosphatidylinositol hy-
drolysis, and thereby increase cellular diacyiglycerol production
and activate PKC. High glucose concentrations also increase
PKC, but do so by increasing the de novo synthesis of diacylglyc-
erol [48, 61]. Perhaps by a direct nuclear effect [45] PKC may
increase the synthesis and secretion of latent TGF-j3. PKC may
also be involved in the conversion of latent TGF-f3 to the
biologically active form by pathways yet to be explored. Active
TGF-13 then functions in an autocrine fashion to stimulate sus-
tained matrix protein synthesis in MC, inhibit matrix degradation
[18, 19], and thereby possibly contribute to the pathogenesis of
glomerulosclerosis. However, as noted above, activation of PKC
by TX, and possibly other agonists, also results in a rapid increase
in Fn synthesis which does not appear to involve TGF-j3. The
relevance of this early PKC action to the sustained stimulation of
matrix production by the MC is not certain.
Reprint requests to Dr. Rebecca K Studer, VAMC, University Drive C,
Pittsbu,gh, Pennsylvania 15240, USA.
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